EValuating Glucose ContrOL Using a Next-GeneraTION Automated Insulin Delivery Algorithm in Patients with Type 1 and Type 2 Diabetes: The EVOLUTION Study
Authors' conclusion
In conclusion, a next-generation AID algorithm demonstrated feasibility in people with diabetes.
Study context
- Population
- Adults with T1D or T2D; 14-day run-in on usual therapy, 48-h hotel automated insulin delivery (AID) (T1D only), up to 6 weeks outpatient AID9 T1D + 8 T2D completed outpatient
- Participants
- 12 vs 8
- Comparison
- Next-generation AID algorithm for Omnipod, with vs without manual boluses, vs usual therapy run-in
- T1Dn = 12
- T2Dn = 8
- Outcome
- Outpatient % CGM readings >250 mg/dL
- Follow-up
- Baseline to outpatient phase
Methodological detailsmultiphase, hotel setting (T1D only), outpatient
- Multiphase
- Hotel setting (T1D only)
- Outpatient
Main finding
As reported in the abstract
- T1D: baseline
- 33.5%
- T1D: with manual boluses
- 9.4%
- T1D: without manual boluses
- 14.3%
- T2D: baseline
- 20.8%
- T2D: with manual boluses
- 7.7%
- T2D: without manual boluses
- 10.5%
Further findings
Time below 70 mg/dL · all phases
- Remained <4% during all phases
Safety
- No adverse events occurred
Original publication
EValuating Glucose ContrOL Using a Next-GeneraTION Automated Insulin Delivery Algorithm in Patients with Type 1 and Type 2 Diabetes: The EVOLUTION Study. Diabetes Technol Ther. Published 27 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →